Skip to main content
SpringerLink
Log in

D2-receptor imaging with [123I]IBZM and Single Photon Emission Tomography in psychiatry: a survey of current status

  • Full Papers
  • Published:
Journal of Neural Transmission / General Section JNT Aims and scope Submit manuscript

Summary

D2-dopamine receptors can be visualized in the human brain in vivo by Single Photon Emission Tomography (SPECT) and the radiolabeled benzamide [123I]IBZM. The present paper reviews the current status of this type of functional brain imaging with respect to basic methodological aspects, data analysis and quantification. The results from published clinical studies in different psychiatric patient populations and normal controls with [123I]IBZM are reviewed. [123I]IBZM-SPECT is a powerful tool for the investigation of D2-dopamine receptor status in psychiatric disorders, different types of drug treatment as well as therapeutic and side effects of pharmacologic agents. However, there still is a need for standardized imaging times and image-processing procedures. Advantages and disadvantages of SPECT with special regard to Positron Emission Tomography (PET) are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Berding G, Gratz KF, Kolbe H, Hundeshagen H (1992) Dopamin D-2 receptor imaging with (I-123) IBZM SPECT: methodical aspects and clinical results. Eur J Nucl Med 19: 735

    Google Scholar 

  • Beuthien-Baumann B, Knop J, Montz R (1992) Zeitabhängigkeit von Quotientenmessungen in der Dopamin-D2-Rezeptorszintigraphie mit 123J-IBZM. Nucl Med 31: A82 (Abstract)

    Google Scholar 

  • Brodie JD, Dewey SL, Wolf AP, Smith GS (1993) Imaging neuroreceptors with positron emission tomography: a new strategy for measuring pharmacological activity in the treatment of schizophrenia. In: Maurer K (ed) Imaging of the brain in psychiatry and related fields. Springer, Berlin Heidelberg New York Tokyo, pp 153–161

    Google Scholar 

  • Broich D, Kasper S, Grünwald F, Danos P, Klemm E, Biersack HJ, Möller HJ (1993) Darstellung von Dopamin-D2-Rezeptoren mittels123J-IBZM-SPECT bei schizophrenen Patienten. In: Baumann P (Hrsg) Biologische Psychiatrie der Gegenwart. Springer, Wien New York, pp 511–513

    Google Scholar 

  • Brücke T, Podreka I, Angelberger P et al. (1991) Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11: 220–228

    PubMed  Google Scholar 

  • Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339: 497

    PubMed  Google Scholar 

  • Brücke T, Wöber C, Strobl R, Wenger S, Asenbaum S, Wöber-Bingöl, Podreka I (1993) In vivo Messung der D2 Rezeptorblockade im Striatum durch verschiedene Neuroleptika und Kalziumantagonisten mit [123J]-Jodobenzamid und der SPECT-Technik. In: Baumann P (Hrsg) Biologische Psychiatrie der Gegenwart. Springer, Wien New York, pp 504–510

    Google Scholar 

  • Camps M, Cortes R, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in human brain, autoradiographic distribution of D2 sites. Neuroscience 28: 275–290

    PubMed  Google Scholar 

  • Coppens HJ, Slooff CJ, Paans AM, Weigman T, Vaalburg W, Korf J (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant patients. Biol Psychiatry 29: 629–634

    PubMed  Google Scholar 

  • Coward DM (1992) General pharmacology of clozapine. Br J Psychiatry 160 [Suppl 17]: 5–11

    Google Scholar 

  • Davis KI, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualisation. Am J Psychiatry 148: 1474–1486

    PubMed  Google Scholar 

  • Farde L, Wiesel MD, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44: 671–672

    PubMed  Google Scholar 

  • Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron Emission Tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544

    PubMed  Google Scholar 

  • Fernandez-Ruiz J, Armor J, Ramos J (1989) Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2 receptors. Brain Res 476: 388–395

    PubMed  Google Scholar 

  • Florvall L, Ogren S (1982) Potential neuroleptic agents. 2,6 Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities. J Med Chem 25: 1280–1286

    PubMed  Google Scholar 

  • Geaney DP, Ellis PM, Soper N, Shepstone BJ, Cowen P (1992) Single Photon Emission Tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol Psychiatry 32: 293–295

    PubMed  Google Scholar 

  • Grünwald F, Danos P, Kasper S, Briele B, Klemm E, Möller HJ, Biersack HJ (1992) IBZM-SPECT bei psychiatrischen Erkrankungen. Nucl Med 31: A 82

    Google Scholar 

  • Harris GJ, Pearlson GD (1993) MRI-guided region of interest placement on emission computed tomograms. Psychiatry Res 50: 57–63

    PubMed  Google Scholar 

  • Herith AJ (1992) The dopamine hypothesis and neurophysiologic concepts in schizophrenia. Rev Neurosci 3: 207–216

    Google Scholar 

  • Herrlinger K, Wagner-Manslau C, van de Flierdt E, Ceballos-Baumann A, Conrad B, Pabst HW (1993) Kinetikstudie von 123-J-Iodobenzamid (IBZM). Nucl Med 32: A15

    Google Scholar 

  • Hertel A, Baas H, Maul FD, Weppner M, Schreiner M, Baum RP, Fischer PA, Hör G (1992) Dopamin-Rezeptor Szintigraphie mit I-123 IBZM beim Parkinson Syndrom. Nucl Med 31: A81 (Abstract)

    Google Scholar 

  • Innis RB, Al-Tikriti M, Woods SW, Zoghbi S, Roth RH, Charney DS, Heninger GR, Smith EO, Zubal IG, Alavi A, Hoffer PB, Kung HF (1990) SPECT imaging of the dopamine D2 receptor in primate brain. J Nucl Med 31: 883 (Abstract)

    Google Scholar 

  • Innis RB, Malison R, Al-Tikriti M, Sybirska E, Zoghbi S, Baldwin RM, Smith E, Elsworth J, Kung HF, Alavi A, Hoffer PB, Roth RH (1991 a) Amphetamine-induced dopamine release competes in vivo for 1-123 IBZM binding to dopamine D2 receptors in non-human primate brain. J Nucl Med 32: 1007–1008

    Google Scholar 

  • Innis R, Tikrit M, Zoghbi S, et al (1991 b) SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves. J Nucl Med 32: 1754–1761

    PubMed  Google Scholar 

  • Johansson L, Mattsson S, Bertil N (1984) Effective dose equivalent from radiopharmaceuticals. Eur J Nucl Med 9: 485–489

    PubMed  Google Scholar 

  • Klemm E, Kasper S, Broich K, Danos P, Grünwald F, Menzel C, Hotze AL, Krappel C, Möller HJ, Biersack HJ (1993)123I-IBZM-SPECT for imaging of striatal D2-dopamine receptors and clinical variables in psychiatric patients with different diagnosis. Pharmacopsychiatry 26: 168

    Google Scholar 

  • Konig P, Benzer MK, Fritzsche H (1991) SPECT technique for visualization of cerebral dopamine D2 receptors. Am J Psychiatry 148: 1607–1608

    Google Scholar 

  • Kung HF, Billings J, Guo YZ, et al (1988) Preparation and biodistribution of [125I]IBZM: a potential CNS D2 dopamine receptor imaging agent. Int J Nucl Med Biol 15: 195–201

    Google Scholar 

  • Kung HF, Pan S, Kung M-P, et al (1989) In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D2-dopamine receptor imaging agent. J Nucl Med 30: 88–92

    PubMed  Google Scholar 

  • Kung HF, Alavi A, Chang W, Kung MP, et al (1990) In vivo SPECT imaging of CNS D2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 31: 573–579

    PubMed  Google Scholar 

  • Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997

    PubMed  Google Scholar 

  • Menzel C, Grünwald F, Klemm E, Broich K, Kasper KS, Reichmann K, Hotze AL, Biersack HJ (1993) Hirn-SPECT mit 123J-markiertem lodobenzamid (IBZM): Aspekte der semiquantitativen Auswertung. Nucl Med 32: 227–230

    Google Scholar 

  • Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227–235

    PubMed  Google Scholar 

  • Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW (1992) Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199–202

    PubMed  Google Scholar 

  • Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a123I IBZM SPET (single photon emission tomography) study. Psychol Med 23: 791–797

    PubMed  Google Scholar 

  • Scherer JS, Tatsch K, Albus M, Schwarz J, Konjarczyk M (1993) D2-dopamine receptor occupancy during treatment with neuroleptics. Pharmacopsychiatry 26: 197

    Google Scholar 

  • Schlegel S, Steinert H, Nickel O, Schlösser R, Hiemke Ch, Wetzel H, Fischer S, Hahn K (1993) IBZM-SPECT bei Neuroleptikatherapie. In: Baumann P (Hrsg) Biologische Psychiatrie der Gegenwart. Springer, Wien New York, pp 520–522

    Google Scholar 

  • Seeman P, Guan H-C, Niznik HB (1989) Endogenous dopamine lowers the dopamine D2-receptor density as measured by [3H]-raclopride. Synapse 3: 96–97

    PubMed  Google Scholar 

  • Seeman P, Hyman BN, Hong-Chang G (1990) Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry 47: 1170–1172

    PubMed  Google Scholar 

  • Seeman P, Hong-Chang G, Van Toi HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441–445

    PubMed  Google Scholar 

  • Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea Ponce Y, Zubal G, Germine M, Smith EO, et al (1992) Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine 123 IBZM. J Nucl Med 33: 1964–1971

    PubMed  Google Scholar 

  • Tatsch K, Schwarz J, Kerner M, Oertel WH, Kirsch CM (1993) Idiopathisches Parkinson Syndrom: 123-J-IBZM SPECT vor und unter Therapie. Nucl Med 32: A13

    Google Scholar 

  • Todd-Pokropek AE (1992) Functional imaging of the brain using Single Photon Emission Computerized Tomography (SPECT). Brain Topogr 2: 119–127

    Google Scholar 

  • Toyama H, Ichise M, Ballinger JR, Fornazzari L, Kirsh JC (1993) Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med 7: 29–38

    PubMed  Google Scholar 

  • Van Hartesveldt C, Joyce J (1986) Effects of estrogen on the basal ganglia. Neurosci Biobeh Rev 10: 1–14

    Google Scholar 

  • Verhoeff NPLG, Van Royen EY, Horn J, et al (1991) Whole body distribution of I-123 Iodobenzamide in 6 healthy human volunteers. J Nucl Med 32: 1018

    Google Scholar 

  • Verhoeff NPLG, Buell U, Costa DC, Kirsch G, Lottes G, Moretti JL, Podreka I, Schober O, van Royen EA (1992) Basics and recommendations for brain SPECT. Nucl Med 31: 114–131

    Google Scholar 

  • Viergever MA, van den Elsen PA, Stokking R (1992) Integrated presentation of multimodal brain images. Brain Topogr 5: 135–145

    PubMed  Google Scholar 

  • Volk S, Maul D, Hör G, Weppner M, Schreiner M, Hertel A, Baas H, Pflug B (1992) D2-receptor occupancy measured by 123I-IBZM-SPECT in chronic schizophrenic patients. In: Neuroimaging in Psychiatry, International Symposium, London (Handbook)

  • Volk S, Maul DF, Weppner M, Schreiner M, Hertel A, Holzmann T, Hör G, Pflug B (1993) D2-receptor occupancy measured by 123 I IBZM-SPECT in chronic schizophrenic patients and its relationship with positive and negative symptomatology. Pharmacopsychiatry 26: 208

    Google Scholar 

  • Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146: 905–908

    PubMed  Google Scholar 

  • Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, et al (1986) Positron Emission Tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558–1563

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. R. Schlösser

    Present address: Department of Psychiatry, University of Mainz, Federal Republic of Germany

Authors and Affiliations

  1. Department of Psychiatry, University of Mainz, Federal Republic of Germany

    S. Schlegel

Authors
  1. R. Schlösser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Schlegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlösser, R., Schlegel, S. D2-receptor imaging with [123I]IBZM and Single Photon Emission Tomography in psychiatry: a survey of current status. J. Neural Transmission 99, 173–185 (1995). https://doi.org/10.1007/BF01271477

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01271477

Keywords

Search

Navigation